natgillin/translations-raw huggingface dataset:
For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution.
U djece u dobi od jedne do pet godina, doza od 1,25 mg jednom na dan uzima se kao sirup ili oralna otopina od 2,5 ml.
For children from six to 11 years of age, the dose is 2.5 mg once a day, taken either as 5 ml of the syrup or oral solution, or as one 2.5 mg orodispersible tablet.
U djece od šest do 11 godina, doza se uzima jednom na dan, i to kao 5 ml sirupa ili oralne otopine ili kao jedna orodisperzibilna tableta od 2,5 mg.
What is Neoclarityn used for?
Za što se Neoclarityn koristi?
For the full list of all side effects reported with Neoclarityn, see the package leaflet.
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Neoclarityn potražite u uputi o lijeku.
What benefit has Neoclarityn shown during the studies?
Koje su koristi lijeka Neoclarityn utvrđene u ispitivanjima?
How is Neoclarityn used?
Kako se Neoclarityn koristi?
How has Neoclarityn been studied?
Kako je Neoclarityn ispitivan?
How does Neoclarityn work?
Kako djeluje Neoclarityn?
Its terminal half-life is 0.6-2 hours.
Njegov terminalni poluvijek je 0,6-2 sata.
Some of these events have been reported more than 1-year after initiation of treatment.
Neki od tih događaja zabilježeni su nakon više od godine dana od početka liječenja.
- If you see or hear things which are not there (hallucinations).
Ako vidite ili čujete stvari koje nisu stvarne (halucinacije).
These cases were considered serious in all reports.
Ti su slučajevi u svim prijavama smatrani ozbiljnima.
Blisters: 3 years Bottles: 3 years
Bočice: 3 godine
Contact you doctor right away if you notice any of the following symptoms.
Odmah se obratite svom liječniku ako primijetite bilo koji od sljedećih simptoma.
- If you have severe liver problems.
- ako imate teške probleme s jetrom.
Hallucinations*, Abnormal dreams
Halucinacije*, Abnormalni snovi
Only single cases of reported cases had not recovered at the time they were reported.
Samo u pojednim od svih prijavljenih slučajeva nije došlo do oporavka u vrijeme prijave.
Tell your doctor or pharmacist if you are smoking or intend to stop smoking.
Obavijestite svog liječnika ili ljekarnika ako pušite ili namjeravate prestati pušiti.
Less than 1% of rasagiline is excreted as unchanged product in urine.
Manje od 1 % razagilina se izlučuje nepromijenjeno u urinu.
Take the next dose normally, when it is time to take it.
Uzmite sljedeću dozu u uobičajeno vrijeme.
Parkinson's disease is associated with symptoms of hallucinations and confusion.
Parkinsonova bolest se povezuje sa simptomima halucinacija i konfuzije.
Teva Operations Poland Sp.z o.o.
Teva Operations Poland Sp.z o.o. ul.
Your doctor may need to adjust or stop your dose (see section 4).
Vaš liječnik će možda morati prilagoditi dozu ili prekinuti liječenje (vidjeti dio 4).
Smoking could decrease the amount of Rasagiline ratiopharm in the blood.
Pušenje može smanjiti količinu Razagilin ratiopharma u krvi.
Talk to your doctor before taking Rasagiline ratiopharm - If you have any liver problems - You should speak with your doctor about any suspicious skin changes.
Obratite se svom liječniku prije nego uzmete Razagilin ratiopharm - ako imate bilo kakve probleme s jetrom - morali biste razgovarati sa svojim liječnikom o bilo kakvim sumnjivim promjenama na koži.
4.5 Interaction with other medicinal products and other forms of interaction MAO Inhibitors
4.5 Interakcije s drugim lijekovima i drugi oblici interakcija MAO inhibitori
No change in dose is required for elderly patients (see section 5.2).
Nije potrebna promjena doze kod starijih bolesnika (vidjeti dio 5.2).
It can be used together with or without Levodopa (another medicine that is used to treat Parkinson's disease).
Može se primjeniti zajedno s levodopom ili bez levodope (drugi lijek koji se primjenjuje za liječenje Parkinsonove bolesti).
Pharmacotherapeutic group: Anti-Parkinson-Drugs, monoamine oxidase -B inhibitors, ATC code: N04BD02
Farmakoterapijska skupina: Antiparkinsonici, inhibitori monoaminooksidaze B, ATK oznaka: N04BD02
For further information please refer to section driving and using machines.
Za više informacija proučite dio o upravljanju vozilima i radu sa strojevima.
Adverse reactions are listed below in Tables 1 and 2 by system organ class and frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene u tablicama 1 i 2 prema klasifikaciji organskih sustava i učestalosti prema sljedećem pravilu: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1 000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1 000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
These symptoms may resemble those observed with nonselective MAO inhibitors.
Ovi simptomi mogu nalikovati na one opažene kod neselektivnih MAO inhibitora.
Decreasing the dose of levodopa may ameliorate this adverse reaction.
Sniženje doze levodope može ublažiti ovu nuspojavu.
This might be enhanced if you take other medicines to treat the symptoms of your Parkinson's disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking Rasagiline ratiopharm.
To se može pojačati ako uzimate druge lijekove za liječenje simptoma Parkinsonove bolesti ili ako uzimate lijekove koji Vas mogu omamiti ili pijete alkohol dok uzimate Razagilin ratiopharm.
- Elevated blood pressure - Excessive drowsiness - Sudden onset of sleep
- povišeni krvni tlak - prekomjerna omamljenost - iznenadni nastup sna
White, high-density polyethylene bottle with or without a child-resistant cap containing 30 tablets.
Bijele bočice od polietilena visoke gustoće sa ili bez sigurnosnog zatvarača za djecu koje sadržavaju 30 tableta.
12 January 2015
Datum prvog odobrenja: 12. siječanj 2015.
Skin carcinoma
Karcinom kože
If you take more Rasagiline ratiopharm than you should If you think that you may have taken too many Rasagiline ratiopharm tablets, contact your doctor or pharmacist immediately.
Ako uzmete više Razagilin ratiopharma nego što ste trebali Ako mislite da ste možda uzeli previše Razagilin ratiopharm tableta, odmah se obratite svom liječniku ili ljekarniku.
Tyramine/rasagiline interaction
Tiramin/razagilin interakcija
Non-clinical data reveal no special hazard for humans based on the standard studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, reproduction and development.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala, reproduktivne i razvojne toksičnosti.
These results indicate that rasagiline's therapeutic concentrations are unlikely to cause any clinically significant interference with substrates of these enzymes (see section 5.3).
Ovi rezultati indiciraju da nije vjerojatno da terapijske koncentracije razagilina prouzročuju bilo kakvu klinički značajnu interferenciju sa supstratima ovih enzima (vidjeti dio 5.3).
Malignant melanoma
Maligni melanom
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na reprodukciju (vidjeti dio 5.3).
Age has little influence on rasagiline pharmacokinetics in the elderly (> 65 years) (see section 4.2)
Dob slabo utječe na farmakokinetiku razagilina u starijih osoba (> 65 godina) (vidjeti dio 4.2).
As a precautionary measure, it is preferable to avoid the use of rasagiline during pregnancy.
Kao mjera opreza, preporučuje se izbjegavati primjenu razagilina tijekom trudnoće.
Depression, Hallucinations*
Depresija Halucinacije*
If increased somnolence or new episodes of falling asleep during activities of daily living (e.g. watching television, passenger in a car, etc.) are experienced at any time during treatment, the patients should not drive or participate in potentially dangerous activities.
U slučaju povećane somnolencije ili novih epizoda nastupa sna tijekom dnevnih aktivnosti (primjerice, gledanja televizije, vožnje u automobilu kao putnik itd.) bilo kada tijekom liječenja, bolesnik ne smije voziti niti sudjelovati u potencijalno opasnim aktivnostima.
Additional cases of malignant melanoma were reported during post-marketing period.
Dodatni slučajevi malignog melanoma prijavljeni su tijekom razdoblja nakon stavljanja lijeka u promet.
7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets 10 x 1 tablets 30 x 1 tablets 100 x 1 tablets
7 tableta 10 tableta 28 tableta 30 tableta 100 tableta 112 tableta 10 x 1 tableta 30 x 1 tableta 100 x 1 tableta
Prilaz baruna Filipovica 25 10000 Zagreb Croatia
Pliva Hrvatska d.o.o Prilaz baruna Filipovića 25 10000 Zagreb Hrvatska
The absolute bioavailability of a single rasagiline dose is about 36%.
Apsolutna bioraspoloživost pojedinačne doze razagilina je oko 36 %.
Take the Rasagiline ratiopharm carton/ blister or bottle with you to show the doctor or pharmacist.
Ponesite sa sobom kutiju/blister ili bočicu Razagilin ratiopharma da pokažete svom liječniku ili ljekarniku.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines (see section 4.7).
Bolesnici koji su osjetili somnolenciju i/ili epizodu iznenadnog nastupa sna moraju se suzdržati od upravljanja vozilima i rada sa strojevima (vidjeti dio 4.7).
Rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/day).
Razagilin selektivno inhibira MAO-B te nije povezan s povećanom osjetljivošću na tiramin pri naznačenoj dozi (1 mg/dan).
Patients should not drive, operate machinery, or work at heights during treatment if they have previously experienced somnolence and/or have fallen asleep without warning prior to use of rasagiline.
Bolesnici ne smiju voziti, upravljati strojevima ili raditi na visinama tijekom liječenja ako su prethodno osjećali somnolenciju i/ili zaspali bez upozorenja prije primjene razagilina.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
Metabolizam razagilina se odvija kroz dva glavna puta: N-dealkilacijom i/ili hidroksilacijom te nastaju: 1-aminoindan, 3-hidroksi-N-propargil-1 aminoindan i 3-hidroksi-1 aminoindan.
These adverse reactions were not associated with an elevated rate of drug discontinuation.
Te nuspojave nisu bile povezane s povećanom stopom prestanka primjene lijeka.
*See section description of selected adverse reactions
*Vidjeti dio s opisom odabranih nuspojava
Rasagiline ratiopharm helps to increase and sustain levels of dopamine in the brain.
Razagilin ratiopharm pomaže u povećavanju i održavanju razina dopamina u mozgu.
Abdominal pain, Constipation, Nausea and vomiting, Dry mouth
Bol u abdomenu, Konstipacija, Mučnina i povraćanje, Suha usta
SNRI/SSRI/tri- and tetracyclic antidepressants
SNRI/SSRI/triciklički i tetraciklički antidepresivi
Although many of these patients reported somnolence while on rasagiline with other dopaminergic medicinal products, some perceived that they had no warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event.
Iako je većina ovih bolesnika prijavila somnolenciju dok je primala razagilin u kombinaciji s drugim dopaminergičkim lijekovima, neki nisu osjetili znakove upozorenja poput prekomjerne omamljenosti i vjerovali su da su neposredno prije događaja bili prisebni.
You should avoid taking Rasagiline ratiopharm if you are pregnant, as the effects of Rasagiline ratiopharm on pregnancy and the unborn child are not known.
Trebali biste izbjegavati uzimanje Razagilin ratiopharma ako ste trudni, jer nije poznato kako Razagilin ratiopharm utječe na trudnoću i nerođeno dijete.
Adverse reactions were mild or moderate and not related to rasagiline treatment.
Nuspojave su bile blage ili umjerene i nisu bile povezane s liječenjem razagilinom.
After oral administration of 14C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days.
Nakon peroralne primjene 14C-označenog razagilina, eliminacija se primarno odvija urinom (62,6 %), a sekundarno putem fecesa (21,8 %), s potpunim izlučivanjem 84,4 % doze lijeka tijekom razdoblja od 38 dana.
Patients with Parkinson's disease are particularly vulnerable to the adverse reactions of hypotension due to existing gait issues.
Bolesnici s Parkinsonovom bolesti posebno su osjetljivi na nuspojave hipotenzije zbog postojećih problema s hodanjem.
Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that rasagiline does not affect them adversely.
Bolesnici trebaju biti oprezni pri upravljanju opasnim strojevima, uključujući motorna vozila, dok nisu dovoljno sigurni da razagilin na njih ne utječe štetno.
Skin melanoma*
Melanom kože*
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with rasagiline.
Bolesnike treba obavijestiti o tome i savjetovati ih da budu oprezni dok upravljaju vozilima ili rade sa strojevima tijekom terapije razagilinom.
Aluminium/aluminium blister packs of 7, 10, 28, 30, 100 or 112 tablets.
Aluminij/aluminij blister pakiranja od 7, 10, 28, 30, 100 ili 112 tableta.
Food does not affect the Tmax of rasagiline, although Cmax and exposure (AUC) are decreased by approximately 60% and 20%, respectively, when the medicinal product is taken with a high fat meal.
Hrana ne utječe na Tmax razagilina, iako je Cmax smanjen za približno 60 %, a izloženost (AUC) za približno 20 % kada se lijek uzima s obrokom s visokim udjelom masnoća.
The recommended dose of rasagiline is 1 mg (one tablet of Rasagiline ratiopharm) once daily, to be taken with or without levodopa.
Preporučena doza razagilina je 1 mg (jedna tableta lijeka Razagilin ratiopharm) jednom dnevno koja se uzima s levodopom ili bez nje.
Rasagiline pharmacokinetics is linear with dose over the range of 0.5-2 mg in Parkinson's disease patients.
Farmakokinetika razagilina je linearna s dozama u rasponu od 0,5-2 mg u bolesnika s Parkinsonovom bolešću.
In post-marketing experience, these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.
U iskustvu nakon stavljanja lijeka u promet, ovi su simptomi opaženi i u bolesnika s Parkinsonovom bolešću liječenih razagilinom.
Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, bočici ili blisteru iza oznake „EXP“ ili „Rok valjanosti“.
Excessive daily sleepiness (hypersomnia, lethargy, sedation, sleep attacks, somnolence, sudden onset of sleep) can occur in patients treated with dopamine agonists and/or other dopaminergic treatments.
Prekomjerna dnevna pospanost (hipersomnija, letargija, sedacija, napadaji sna, somnolencija, iznenadni nastup sna) mogu se javiti kod bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima.
Injury, poisoning and procedural complications
Ozljede, trovanja i procedu ralne komplik acije
Results of five tyramine challenge studies (in volunteers and Parkinson's disease patients), together with results of home monitoring of blood pressure after meals (of 464 patients treated with 0.5 or 1 mg/day of rasagiline or placebo as adjunct therapy to levodopa for six months without tyramine restrictions), and the fact that there were no reports of tyramine/rasagiline interaction in clinical studies conducted without tyramine restriction, indicate that rasagiline can be used safely without dietary tyramine restrictions.
Rezultati iz pet ispitivanja izloženosti tiraminu (u dobrovoljaca i bolesnika s Parkinsonovom bolešću), zajedno s rezultatima kućnog nadziranja krvnog tlaka nakon obroka (464 bolesnika liječenih s 0,5 ili 1 mg/dan razagilina ili placebom kao dodatnom terapijom levodopi kroz šest mjeseci bez restrikcija tiramina) i činjenicom da nije bilo prijava tiramin/razagilin interakcija u kliničkim ispitivanjima provedenim bez restrikcije tiramina, upućuju na to da se razagilin može primijenjivati sigurno bez dijetalnih restrikcija tiramina.
Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects.
Karakteristike farmakokinetike razagilina u osoba s blagim (CLcr 50-80 ml/min) i umjerenim (CLcr 30-49 ml/min) oštećenjem bubrega su slične onima zdravih osoba.
Rasagiline was not carcinogenic in rats at systemic exposure, 84 - 339 times the expected plasma exposures in humans at 1 mg/day.
Razagilin nije bio kancerogen u štakora pri sistemskoj ekspoziciji 84-339 puta većoj od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Since rasagiline potentiates the effects of levodopa, the adverse reactions of levodopa may be increased and pre-existing dyskinesia exacerbated.
Budući da razagilin pojačava učinke levodope, nuspojave levodope mogu se povećati i već postojeća diskinezija pogoršati.
Symptoms reported following overdose of Rasagiline ratiopharm included slightly euphoric mood (light form of mania), extremely high blood pressure and serotonin syndrome (see section 4).
Simptomi zabilježeni nakon predoziranja Razagilin ratiopharmom uključivali su blago euforično raspoloženje (blagi oblik manije), krajnje visok krvni tlak i serotoninski sindrom (vidjeti dio 4).
In mice, increased incidences of combined bronchiolar/alveolar adenoma and/or carcinoma were observed at systemic exposures, 144 - 213 times the expected plasma exposure in humans at 1 mg/day.
U miševa je opažena povećana incidencija kombiniranih bronhiolarnih/alveolarnih adenoma i/ili karcinoma pri sistemskim ekspozicijama 144-213 puta većim od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Concomitant use of rasagiline with other medicinal products
Istodobna primjena razagilina s drugim lijekovima
The use of Rasagiline ratiopharm together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.
Istodobnu primjenu Razagilin ratiopharma s antidepresivima koji sadrže fluoksetin ili fluvoksamin potrebno je izbjegavati.
Non-clinical data indicate that rasagiline inhibits prolactin secretion and thus, may inhibit lactation.
Neklinički podaci pokazuju da razagilin inhibira sekreciju prolaktina i prema tome, može inhibirati laktaciju.
- Involuntary movements (dyskinesia) - Headache
- nevoljni pokreti (diskinezija) - glavobolja
Fever, Malaise
Vrućica, Malaksalost
Patients should be cautioned about possible additive effects of sedating medicinal products, alcohol, or other central nervous system depressants (e.g. benzodiazepines, antipsychotics, antidepressants) in combination with rasagiline, or when taking concomitant medications that increase plasma levels of rasagiline (e.g. ciprofloxacin) (see section 4.4).
Bolesnike treba upozoriti na moguće dodatne učinke lijekova za smirenje, alkohola ili drugih depresora središnjeg živčanog sustava (primjerice benzodiazepina, antipsihotika, antidepresiva) u kombinaciji s razagilinom ili prilikom istodobnog uzimanja lijekova koji povećavaju razine razagilina u plazmi (primjerice ciprofloksacin) (vidjeti dio 4.4).
Co-administration of rasagiline and ciprofloxacin (an inhibitor of CYP1A2) increased the AUC of rasagiline by 83%.
Istodobna primjena razagilina i ciprofloksacina (inhibitora CYP1A2) je povećala AUC razagilina za 83 %.
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included hypomania, hypertensive crisis and serotonin syndrome.
Simptomi prijavljeni nakon predoziranja razagilinom u dozama u rasponu od 3 mg do 100 mg uključivali su hipomaniju, hipertenzivnu krizu i serotoninski sindrom.
Patients being treated with rasagiline and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until they have gained sufficient experience with rasagiline and other dopaminergic medications to gauge whether or not it affects their mental and/or motor performance adversely.
Bolesnike koji se liječe razagilinom te koji osjećaju somnolenciju i/ili imaju epizode iznenadnog nastupa sna treba obavijestiti da se suzdrže od vožnje ili sudjelovanja u aktivnostima pri kojima narušena pozornost može njih ili druge dovesti u opasnost od ozbiljne ozljede ili smrti (primjerice upravljanje strojevima) sve dok ne steknu dovoljno iskustva s razagilinom i drugim dopaminergičkim lijekovima kako bi mogli prosuditi utječe li lijek negativno na njihove mentalne i/ili motoričke sposobnosti.
Ex vivo and in vitro experiments demonstrate that rasagiline is neither inhibitor nor inducer of major CYP450 enzymes (see section 4.5).
Ex vivo te in vitro eksperimenti pokazuju da razagilin niti inhibira niti inducira glavne enzime sustava CYP450 (vidjeti dio 4.5).
In patients experiencing somnolence/sudden sleep episodes, rasagiline may have major influence on the ability to drive and use machines.
U bolesnika koji osjete somnolenciju/epizode iznenadnog nastupa sna, razagilin može značajno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
In the post-marketing period, cases of elevated blood pressure, including rare serious cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline.
U razdoblju nakon stavljanja lijeka u promet prijavljeni su slučajevi povišenog krvnog tlaka, uključujući i rijetke ozbiljne slučajeve hipertenzivne krize povezane s ingestijom nepoznatih količina hrane bogate tiraminom u bolesnika koji su uzimali razagilin.
Rasagiline ratiopharm may be taken with or without food.
Razagilin ratiopharm se može uzeti sa ili bez hrane.
Rasagiline ratiopharm may cause drowsiness and may cause you to suddenly fall asleep during day time activities, especially if you are taking other dopaminergic medicinal products (used for the treatment of Parkinson's disease).
Razagilin ratiopharm može uzrokovati omamljenost i može učiniti da iznenada zaspite tijekom dnevnih aktivnosti, posebice ako uzimate dopaminergičke lijekove (primjenjuju se za liječenje Parkinsonove bolesti).
Rasagiline clinical trials did not allow concomitant use of fluoxetine or fluvoxamine with rasagiline, but the following antidepressants and doses were allowed in the rasagiline trials: amitriptyline ≤ 50 mg/daily, trazodone ≤ 100 mg/daily, citalopram ≤ 20 mg/daily, sertraline ≤ 100 mg/daily, and paroxetine ≤ 30 mg/daily (see section 4.5).
U kliničkim ispitivanjima razagilina nije bila dozvoljena istodobna upotreba fluoksetina ili fluvoksamina s razagilinom, ali sljedeći antidepresivi i doze bili su dozvoljeni u ispitivanjima razagilina: amitriptilin ≤ 50 mg/dnevno, trazodon ≤ 100 mg/dnevno, citalopram ≤ 20 mg/dnevno, sertralin ≤ 100 mg/dnevno i paroksetin ≤ 30 mg/dnevno (vidjeti dio 4.5).
How to store Rasagiline ratiopharm Contents of the pack and other information
Kako čuvati Razagilin ratiopharm Sadržaj pakiranja i druge informacije
Non-clinical data indicate that rasagiline has no effect on fertility.
Neklinički podaci pokazuju da razagilin ne utječe na plodnost.
Concomitant use of rasagiline and levodopa
Istodobna primjena razagilina i levodope